How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/recurrent-genital-herpes-simplex.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Recurrent genital herpes simplex — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recurrent genital herpes simplex (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Recurrent genital herpes simplex, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Valtrex	valaciclovir	GSK	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor		1995-01-01
Famvir	FAMCICLOVIR	Novartis	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]		1994-01-01
Zovirax	ACYCLOVIR	Ligand Pharms	Herpes Simplex Virus Nucleoside Analog DNA Polymerase Inhibitor [EPC]	Purine nucleoside phosphorylase	1982-01-01
Aciclovir	Aciclovir	Assistance Publique Hopitaux De Marseille		Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase
ACYC	ACYC	Ligand Pharms		Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Ligand Pharms · 2 drugs in Recurrent genital herpes simplex
Assistance Publique Hopitaux De Marseille · 1 drug in Recurrent genital herpes simplex
GSK · 1 drug in Recurrent genital herpes simplex
Novartis · 1 drug in Recurrent genital herpes simplex

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Recurrent genital herpes simplex:

Cite this brief

Drug Landscape (2026). Recurrent genital herpes simplex — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/recurrent-genital-herpes-simplex. Accessed 2026-06-10.

Recurrent genital herpes simplex full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing